Details
Stereochemistry | MIXED |
Molecular Formula | C7H15Cl2N2O3P |
Molecular Weight | 277.085 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1CCOP(=O)(N1)N(CCCl)CCCl
InChI
InChIKey=RANONBLIHMVXAJ-UHFFFAOYSA-N
InChI=1S/C7H15Cl2N2O3P/c8-2-4-11(5-3-9)15(13)10-7(12)1-6-14-15/h7,12H,1-6H2,(H,10,13)
Molecular Formula | C7H15Cl2N2O3P |
Molecular Weight | 277.085 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Cyclophosphamide (the generic name for Cytoxan, Neosar, Revimmune), also known as cytophosphane, is a nitrogen mustard alkylating agent, from the oxazophorines group. It is used to treat various types of cancer and some autoimmune disorders. It is a "prodrug"; it is converted in the liver to active forms that have chemotherapeutic activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311221 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CYTOXAN Approved UseTo treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients. Launch Date1960 |
|||
Primary | CYTOXAN Approved UseTo treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients. Launch Date1960 |
|||
Primary | CYTOXAN Approved UseTo treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients. Launch Date1960 |
|||
Primary | CYTOXAN Approved UseTo treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients. Launch Date1960 |
|||
Primary | CYTOXAN Approved UseTo treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients. Launch Date1960 |
|||
Primary | CYTOXAN Approved UseTo treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients. Launch Date1960 |
|||
Primary | CYTOXAN Approved UseTo treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients. Launch Date1960 |
|||
Primary | CYTOXAN Approved UseTo treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients. Launch Date1960 |
|||
Primary | CYTOXAN Approved UseTo treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients. Launch Date1960 |
|||
Primary | CYTOXAN Approved UseTo treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients. Launch Date1960 |
|||
Primary | CYTOXAN Approved UseTo treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients. Launch Date1960 |
|||
Primary | CYTOXAN Approved UseTo treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients. Launch Date1960 |
|||
Primary | CYTOXAN Approved UseTo treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients. Launch Date1960 |
|||
Primary | CYTOXAN Approved UseTo treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients. Launch Date1960 |
|||
Primary | CYTOXAN Approved UseTo treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients. Launch Date1960 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1234 μg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24022191 |
50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: Imatinib | Bevacizumab |
CYCLOPHOSPHAMIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
17587 μg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24022191 |
50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: Imatinib | Bevacizumab |
CYCLOPHOSPHAMIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10.8 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24022191 |
50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: Imatinib | Bevacizumab |
CYCLOPHOSPHAMIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
80% |
CYCLOPHOSPHAMIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg/m2 2 times / day multiple, intravenous MTD Dose: 200 mg/m2, 2 times / day Route: intravenous Route: multiple Dose: 200 mg/m2, 2 times / day Co-administed with:: Clofarabine, i.v(40 mg/m(2) daily × 3 days) Sources: Page: p.5, 16 |
unhealthy, 21-72 n = 5 Health Status: unhealthy Condition: Acute lymphoblastic leukemia Age Group: 21-72 Sex: M+F Population Size: 5 Sources: Page: p.5, 16 |
Other AEs: Bilirubin total increased, Diarrhea... Other AEs: Bilirubin total increased (grade 3, 20%) Sources: Page: p.5, 16Diarrhea (grade 3, 20%) |
300 mg/m2 2 times / day multiple, intravenous Studied dose Dose: 300 mg/m2, 2 times / day Route: intravenous Route: multiple Dose: 300 mg/m2, 2 times / day Co-administed with:: Clofarabine, i.v(40 mg/m(2) daily × 3 days) Sources: Page: p.5, 16 |
unhealthy, 21-72 n = 25 Health Status: unhealthy Condition: Acute lymphoblastic leukemia Age Group: 21-72 Sex: M+F Population Size: 25 Sources: Page: p.5, 16 |
DLT: Diarrhea, Lipase increased... Dose limiting toxicities: Diarrhea (grade 3-5, 12%) Sources: Page: p.5, 16Lipase increased (grade 4, 4%) Transaminases increased (grade 3-5, 12%) Nausea and vomiting (grade 3-5, 4%) |
3300 mg/m2 single, intravenous Highest studied dose Dose: 3300 mg/m2 Route: intravenous Route: single Dose: 3300 mg/m2 Co-administed with:: paclitaxel, i.v(160 mg/m2) Sources: Page: p.98 |
unhealthy, 26-64 n = 6 Health Status: unhealthy Condition: Breast cancer Age Group: 26-64 Sex: F Population Size: 6 Sources: Page: p.98 |
DLT: Neutropenia, Thrombocytopenia... Dose limiting toxicities: Neutropenia (grade 4, 33.3%) Sources: Page: p.98Thrombocytopenia (16.7%) Neutropenia (16.7%) |
2700 mg/m2 single, intravenous MTD Dose: 2700 mg/m2 Route: intravenous Route: single Dose: 2700 mg/m2 Co-administed with:: paclitaxel, i.v(160 mg/m2) Sources: Page: p.98 |
unhealthy, 26-64 n = 6 Health Status: unhealthy Condition: Breast cancer Age Group: 26-64 Sex: F Population Size: 6 Sources: Page: p.98 |
DLT: Neutropenia, Thrombocytopenia... Dose limiting toxicities: Neutropenia (grade 4, 16.7%) Sources: Page: p.98Thrombocytopenia (16.7%) Neutropenia (16.7%) |
2000 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 2000 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 2000 mg/m2, 1 times / 3 weeks Co-administed with:: paclitaxel, i.v(200 mg/m2, once in 3 weeks, 5 cycles) Sources: Page: p.658 |
unhealthy, 27 - 70 n = 6 Health Status: unhealthy Condition: Breast cancer Age Group: 27 - 70 Sex: F Population Size: 6 Sources: Page: p.658 |
DLT: Febrile neutropenia, Thrombocytopenia... Dose limiting toxicities: Febrile neutropenia (33.3%) Sources: Page: p.658Thrombocytopenia (grade 4, 16.7%) |
100 mg 1 times / day multiple, oral Highest studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Co-administed with:: paclitaxel, i.v(175 mg/m(2) (Day 1), 6 cycles) Sources: Page: p.519 |
unhealthy, 47-78 n = 6 Health Status: unhealthy Condition: Urothelial bladder cancer Age Group: 47-78 Sex: M+F Population Size: 6 Sources: Page: p.519 |
DLT: Neutropenia, Thrombocytopenia... Dose limiting toxicities: Neutropenia (grade 4, 33.3%) Sources: Page: p.519Thrombocytopenia (grade 4, 16.7%) Constipation (grade 3, 16.7%) |
50 mg 1 times / day multiple, oral MTD Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: paclitaxel, i.v(175 mg/m(2) (Day 1), 12 cycles) Sources: Page: p.519 |
unhealthy, 47-78 n = 6 Health Status: unhealthy Condition: Urothelial bladder cancer Age Group: 47-78 Sex: M+F Population Size: 6 Sources: Page: p.519 |
|
5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Disc. AE: Myelosuppression, Immunosuppression... AEs leading to discontinuation/dose reduction: Myelosuppression Sources: Page: p.1Immunosuppression Bone marrow failure Infection Urinary tract toxicity Toxicity renal Cystitis hemorrhagic Pyelitis Ureteritis Hematuria Cardiotoxicity Myocarditis Myopericarditis Pericardial effusion Arrhythmia (NOS) Congestive heart failure Pulmonary toxicity Pneumonitis Pulmonary fibrosis Pulmonary veno-occlusive disease Respiratory failure Metastases Venoocclusive liver disease Fetal damage |
50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Disc. AE: Myelosuppression, Immunosuppression... AEs leading to discontinuation/dose reduction: Myelosuppression Sources: Page: p.1Immunosuppression Bone marrow failure Infection Urinary tract toxicity Toxicity renal Cystitis hemorrhagic Pyelitis Ureteritis Hematuria Cardiotoxicity Myocarditis Myopericarditis Pericardial effusion Arrhythmia (NOS) Congestive heart failure Pulmonary toxicity Pneumonitis Pulmonary fibrosis Pulmonary veno-occlusive disease Respiratory failure Metastases Venoocclusive liver disease Fetal damage |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Bilirubin total increased | grade 3, 20% | 200 mg/m2 2 times / day multiple, intravenous MTD Dose: 200 mg/m2, 2 times / day Route: intravenous Route: multiple Dose: 200 mg/m2, 2 times / day Co-administed with:: Clofarabine, i.v(40 mg/m(2) daily × 3 days) Sources: Page: p.5, 16 |
unhealthy, 21-72 n = 5 Health Status: unhealthy Condition: Acute lymphoblastic leukemia Age Group: 21-72 Sex: M+F Population Size: 5 Sources: Page: p.5, 16 |
Diarrhea | grade 3, 20% | 200 mg/m2 2 times / day multiple, intravenous MTD Dose: 200 mg/m2, 2 times / day Route: intravenous Route: multiple Dose: 200 mg/m2, 2 times / day Co-administed with:: Clofarabine, i.v(40 mg/m(2) daily × 3 days) Sources: Page: p.5, 16 |
unhealthy, 21-72 n = 5 Health Status: unhealthy Condition: Acute lymphoblastic leukemia Age Group: 21-72 Sex: M+F Population Size: 5 Sources: Page: p.5, 16 |
Diarrhea | grade 3-5, 12% DLT |
300 mg/m2 2 times / day multiple, intravenous Studied dose Dose: 300 mg/m2, 2 times / day Route: intravenous Route: multiple Dose: 300 mg/m2, 2 times / day Co-administed with:: Clofarabine, i.v(40 mg/m(2) daily × 3 days) Sources: Page: p.5, 16 |
unhealthy, 21-72 n = 25 Health Status: unhealthy Condition: Acute lymphoblastic leukemia Age Group: 21-72 Sex: M+F Population Size: 25 Sources: Page: p.5, 16 |
Transaminases increased | grade 3-5, 12% DLT |
300 mg/m2 2 times / day multiple, intravenous Studied dose Dose: 300 mg/m2, 2 times / day Route: intravenous Route: multiple Dose: 300 mg/m2, 2 times / day Co-administed with:: Clofarabine, i.v(40 mg/m(2) daily × 3 days) Sources: Page: p.5, 16 |
unhealthy, 21-72 n = 25 Health Status: unhealthy Condition: Acute lymphoblastic leukemia Age Group: 21-72 Sex: M+F Population Size: 25 Sources: Page: p.5, 16 |
Nausea and vomiting | grade 3-5, 4% DLT |
300 mg/m2 2 times / day multiple, intravenous Studied dose Dose: 300 mg/m2, 2 times / day Route: intravenous Route: multiple Dose: 300 mg/m2, 2 times / day Co-administed with:: Clofarabine, i.v(40 mg/m(2) daily × 3 days) Sources: Page: p.5, 16 |
unhealthy, 21-72 n = 25 Health Status: unhealthy Condition: Acute lymphoblastic leukemia Age Group: 21-72 Sex: M+F Population Size: 25 Sources: Page: p.5, 16 |
Lipase increased | grade 4, 4% DLT |
300 mg/m2 2 times / day multiple, intravenous Studied dose Dose: 300 mg/m2, 2 times / day Route: intravenous Route: multiple Dose: 300 mg/m2, 2 times / day Co-administed with:: Clofarabine, i.v(40 mg/m(2) daily × 3 days) Sources: Page: p.5, 16 |
unhealthy, 21-72 n = 25 Health Status: unhealthy Condition: Acute lymphoblastic leukemia Age Group: 21-72 Sex: M+F Population Size: 25 Sources: Page: p.5, 16 |
Neutropenia | 16.7% DLT |
3300 mg/m2 single, intravenous Highest studied dose Dose: 3300 mg/m2 Route: intravenous Route: single Dose: 3300 mg/m2 Co-administed with:: paclitaxel, i.v(160 mg/m2) Sources: Page: p.98 |
unhealthy, 26-64 n = 6 Health Status: unhealthy Condition: Breast cancer Age Group: 26-64 Sex: F Population Size: 6 Sources: Page: p.98 |
Thrombocytopenia | 16.7% DLT |
3300 mg/m2 single, intravenous Highest studied dose Dose: 3300 mg/m2 Route: intravenous Route: single Dose: 3300 mg/m2 Co-administed with:: paclitaxel, i.v(160 mg/m2) Sources: Page: p.98 |
unhealthy, 26-64 n = 6 Health Status: unhealthy Condition: Breast cancer Age Group: 26-64 Sex: F Population Size: 6 Sources: Page: p.98 |
Neutropenia | grade 4, 33.3% DLT |
3300 mg/m2 single, intravenous Highest studied dose Dose: 3300 mg/m2 Route: intravenous Route: single Dose: 3300 mg/m2 Co-administed with:: paclitaxel, i.v(160 mg/m2) Sources: Page: p.98 |
unhealthy, 26-64 n = 6 Health Status: unhealthy Condition: Breast cancer Age Group: 26-64 Sex: F Population Size: 6 Sources: Page: p.98 |
Neutropenia | 16.7% DLT |
2700 mg/m2 single, intravenous MTD Dose: 2700 mg/m2 Route: intravenous Route: single Dose: 2700 mg/m2 Co-administed with:: paclitaxel, i.v(160 mg/m2) Sources: Page: p.98 |
unhealthy, 26-64 n = 6 Health Status: unhealthy Condition: Breast cancer Age Group: 26-64 Sex: F Population Size: 6 Sources: Page: p.98 |
Thrombocytopenia | 16.7% DLT |
2700 mg/m2 single, intravenous MTD Dose: 2700 mg/m2 Route: intravenous Route: single Dose: 2700 mg/m2 Co-administed with:: paclitaxel, i.v(160 mg/m2) Sources: Page: p.98 |
unhealthy, 26-64 n = 6 Health Status: unhealthy Condition: Breast cancer Age Group: 26-64 Sex: F Population Size: 6 Sources: Page: p.98 |
Neutropenia | grade 4, 16.7% DLT |
2700 mg/m2 single, intravenous MTD Dose: 2700 mg/m2 Route: intravenous Route: single Dose: 2700 mg/m2 Co-administed with:: paclitaxel, i.v(160 mg/m2) Sources: Page: p.98 |
unhealthy, 26-64 n = 6 Health Status: unhealthy Condition: Breast cancer Age Group: 26-64 Sex: F Population Size: 6 Sources: Page: p.98 |
Febrile neutropenia | 33.3% DLT |
2000 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 2000 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 2000 mg/m2, 1 times / 3 weeks Co-administed with:: paclitaxel, i.v(200 mg/m2, once in 3 weeks, 5 cycles) Sources: Page: p.658 |
unhealthy, 27 - 70 n = 6 Health Status: unhealthy Condition: Breast cancer Age Group: 27 - 70 Sex: F Population Size: 6 Sources: Page: p.658 |
Thrombocytopenia | grade 4, 16.7% DLT |
2000 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 2000 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 2000 mg/m2, 1 times / 3 weeks Co-administed with:: paclitaxel, i.v(200 mg/m2, once in 3 weeks, 5 cycles) Sources: Page: p.658 |
unhealthy, 27 - 70 n = 6 Health Status: unhealthy Condition: Breast cancer Age Group: 27 - 70 Sex: F Population Size: 6 Sources: Page: p.658 |
Constipation | grade 3, 16.7% DLT |
100 mg 1 times / day multiple, oral Highest studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Co-administed with:: paclitaxel, i.v(175 mg/m(2) (Day 1), 6 cycles) Sources: Page: p.519 |
unhealthy, 47-78 n = 6 Health Status: unhealthy Condition: Urothelial bladder cancer Age Group: 47-78 Sex: M+F Population Size: 6 Sources: Page: p.519 |
Thrombocytopenia | grade 4, 16.7% DLT |
100 mg 1 times / day multiple, oral Highest studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Co-administed with:: paclitaxel, i.v(175 mg/m(2) (Day 1), 6 cycles) Sources: Page: p.519 |
unhealthy, 47-78 n = 6 Health Status: unhealthy Condition: Urothelial bladder cancer Age Group: 47-78 Sex: M+F Population Size: 6 Sources: Page: p.519 |
Neutropenia | grade 4, 33.3% DLT |
100 mg 1 times / day multiple, oral Highest studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Co-administed with:: paclitaxel, i.v(175 mg/m(2) (Day 1), 6 cycles) Sources: Page: p.519 |
unhealthy, 47-78 n = 6 Health Status: unhealthy Condition: Urothelial bladder cancer Age Group: 47-78 Sex: M+F Population Size: 6 Sources: Page: p.519 |
Arrhythmia (NOS) | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Bone marrow failure | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Cardiotoxicity | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Congestive heart failure | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Cystitis hemorrhagic | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Fetal damage | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Hematuria | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Immunosuppression | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Infection | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Metastases | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Myelosuppression | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Myocarditis | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Myopericarditis | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Pericardial effusion | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Pneumonitis | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Pulmonary fibrosis | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Pulmonary toxicity | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Pulmonary veno-occlusive disease | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Pyelitis | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Respiratory failure | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Toxicity renal | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Ureteritis | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Urinary tract toxicity | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Venoocclusive liver disease | Disc. AE | 5 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 5 mg/kg, 1 times / day Route: oral Route: multiple Dose: 5 mg/kg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Arrhythmia (NOS) | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Bone marrow failure | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Cardiotoxicity | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Congestive heart failure | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Cystitis hemorrhagic | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Fetal damage | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Hematuria | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Immunosuppression | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Infection | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Metastases | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Myelosuppression | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Myocarditis | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Myopericarditis | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Pericardial effusion | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Pneumonitis | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Pulmonary fibrosis | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Pulmonary toxicity | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Pulmonary veno-occlusive disease | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Pyelitis | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Respiratory failure | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Toxicity renal | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Ureteritis | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Urinary tract toxicity | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Venoocclusive liver disease | Disc. AE | 50 mg/kg multiple, intravenous (total|max) Recommended Dose: 50 mg/kg Route: intravenous Route: multiple Dose: 50 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma Sources: Page: p.1 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | yes (co-administration study) Comment: coadministration with ketoconazole: caused a KTZ dose-dependent decrease in main parameters of DECP (Cmax, Tmax, and AUC0–∞) and provided magnitude exposure of DECP (more than a 50% AUC decrease) as a consequence of CYP3A inhibition |
PubMed
Title | Date | PubMed |
---|---|---|
Cyclophosphamide-induced hemorrhagic cystitis in children with leukemia. | 1975 Nov |
|
[Apoptosis of B lymphocytic leukemia induced by anticancer drugs and their cell cycle specificity]. | 1998 Jan |
|
[Crescentic glomerulonephritis with anti neutrophil cytoplasmic antibody in children. Cases report]. | 1999 Aug |
|
Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation. | 1999 Feb |
|
[Veno-occlusive disease of the liver and POEMS syndrome]. | 1999 Feb 20 |
|
Increase of hematopoietic responses by triple or single helical conformer of an antitumor (1-->3)-beta-D-glucan preparation, Sonifilan, in cyclophosphamide-induced leukopenic mice. | 1999 Jan |
|
Evaluation of uroprotective efficacy of amifostine against cyclophosphamide induced hemorrhagic cystitis. | 1999 Mar |
|
Effect of dexamethasone on cyclophosphamide-induced cystitis in rats: lack of relation with bradykinin B1 receptor-mediated motor responses. | 1999 Mar 12 |
|
Delayed methotrexate clearance in a patient with sickle cell anemia and osteosarcoma. | 1999 Mar-Apr |
|
Chlorambucil-induced postclosure exencephaly and axial skeletal abnormalities in rat fetuses. | 1999 May-Jun |
|
Primary desmoplastic small cell tumor of soft tissues and bone of the hand. | 1999 Nov |
|
Ruptured Klebsiella pneumoniae liver abscess after high-dose cyclophosphamide for severe aplastic anemia. | 2000 Jul |
|
Invasive bladder cancer after cyclophosphamide administration for nephrotic syndrome--a case report. | 2000 Jun |
|
QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide. | 2000 Mar 4 |
|
Nitric oxide and NK(1)-tachykinin receptors in cyclophosphamide-induced cystitis, in rats. | 2000 Nov |
|
Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy. | 2000 Oct |
|
A comparative study of sequential priming and mobilisation of progenitor cells with rhG-CSF alone and high-dose cyclophosphamide plus rhG-CSF. | 2000 Oct |
|
Myopericarditis caused by cyclophosphamide used to mobilize peripheral blood stem cells in a myeloma patient with renal failure. | 2000 Sep |
|
Mixed chimerism, heart, and skin allograft tolerance in cyclophosphamide-induced tolerance. | 2000 Sep 27 |
|
Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector. | 2001 Feb 1 |
|
A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide. | 2001 Jun |
|
Leiomyosarcoma of the bladder fourteen years after cyclophosphamide therapy for retinoblastoma. | 2001 Jun |
|
Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology. | 2001 Jun |
|
Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy. | 2001 Jun 1 |
|
Hematopoietic stem cell transplantation for high-risk adult patients with severe aplastic anemia; reduction of graft failure by enhancing stem cell dose. | 2001 Mar |
|
Stem cell toxicity of oxazaphosphorine metabolites in comparison to their antileukemic activity. | 2002 Apr 1 |
|
Aldehyde-dehydrogenase gene-transduced hematopoietic cell line K562 overcomes the cytoxicity of cyclophosphamide in vitro. | 2002 Jun |
|
N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation. | 2003 Aug |
|
A mouse-based strategy for cyclophosphamide pharmacogenomic discovery. | 2003 Oct |
|
Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction. | 2004 Apr |
|
Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. | 2005 Oct |
|
Rapid quantitation of cyclophosphamide metabolites in plasma by liquid chromatography-mass spectrometry. | 2006 May 1 |
|
High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. | 2006 May 8 |
|
A mouse model with liver-specific deletion and global suppression of the NADPH-cytochrome P450 reductase gene: characterization and utility for in vivo studies of cyclophosphamide disposition. | 2007 Apr |
|
Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation. | 2007 Jul |
|
Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS). | 2007 Jul 1 |
|
Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. | 2007 Jun |
|
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. | 2008 Jun |
|
Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. | 2008 Jun 18 |
|
Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen. | 2009 Feb |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Cyclophosphamide can also be administered orally (1 mg per kg per day to 5 mg per kg per day) in malignant diseases.
40-50 mg per kg in divided doses over 2 to 5 days in malignant diseases and 2 mg per kg daily for 8 to 12 weeks in minimal change nephrotic sindrome
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6600859
Curator's Comment: Cyclophosphamide was tested for its ability to inhibit human lymphocyte proliferation and to modulate lymphocyte response to mitogens in vitro. At higher concentrations (20 to 160 ug/ml), the drug had a suppressive effect with a maximum suppression of 99%.
from 20 to 160 ug/ml
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:19:30 GMT 2023
by
admin
on
Sat Dec 16 09:19:30 GMT 2023
|
Record UNII |
1XBF4E50HS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID90960669
Created by
admin on Sat Dec 16 09:19:30 GMT 2023 , Edited by admin on Sat Dec 16 09:19:30 GMT 2023
|
PRIMARY | |||
|
40277-05-2
Created by
admin on Sat Dec 16 09:19:30 GMT 2023 , Edited by admin on Sat Dec 16 09:19:30 GMT 2023
|
PRIMARY | |||
|
1864
Created by
admin on Sat Dec 16 09:19:30 GMT 2023 , Edited by admin on Sat Dec 16 09:19:30 GMT 2023
|
PRIMARY | |||
|
4-Hydroxycyclophosphamide
Created by
admin on Sat Dec 16 09:19:30 GMT 2023 , Edited by admin on Sat Dec 16 09:19:30 GMT 2023
|
PRIMARY | |||
|
SUB126201
Created by
admin on Sat Dec 16 09:19:30 GMT 2023 , Edited by admin on Sat Dec 16 09:19:30 GMT 2023
|
PRIMARY | |||
|
196562
Created by
admin on Sat Dec 16 09:19:30 GMT 2023 , Edited by admin on Sat Dec 16 09:19:30 GMT 2023
|
PRIMARY | |||
|
99735
Created by
admin on Sat Dec 16 09:19:30 GMT 2023 , Edited by admin on Sat Dec 16 09:19:30 GMT 2023
|
PRIMARY | |||
|
1XBF4E50HS
Created by
admin on Sat Dec 16 09:19:30 GMT 2023 , Edited by admin on Sat Dec 16 09:19:30 GMT 2023
|
PRIMARY | |||
|
100000151796
Created by
admin on Sat Dec 16 09:19:30 GMT 2023 , Edited by admin on Sat Dec 16 09:19:30 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |